Allison Armstrong

Allison Armstrong, PhD, is an accomplished executive in the field of drug development and translational medicine, currently serving as the Executive Director and Asset Development Team Leader for Early Clinical Development at Organon since April 2024. Prior to this role, Armstrong spent over a decade at HemoShear Therapeutics, where responsibilities included leading clinical stage programs for rare diseases, managing cross-functional teams, and overseeing the development of key clinical programs, including HST5040 for propionic and methylmalonic acidemia. Armstrong's earlier experience includes a postdoctoral research position in immunology at the University of Virginia, focusing on cellular responses to apoptotic signals. Armstrong holds a PhD in Pharmacology from the University of Virginia and a BS in Biological Sciences with a minor in Chemistry from the University of Delaware.